

GLAXOSMITHKLINE PLC
Form 6-K
April 14, 2009

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending April 2009

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons Discharging Managerial Responsibility or Connected Persons in the Ordinary shares of GlaxoSmithKline plc in respect of the under-mentioned persons arising from the purchase of Ordinary shares at a price of £10.09 per Ordinary share on 9 April 2009 through the Company's ShareReward Plan ("the Plan") which the under-mentioned persons entered on 5 October 2001:

Mr A P Witty	Acquisition of 32 Ordinary shares under the Dividend Reinvestment element of the Plan
Mr J S Heslop	Acquisition of 32 Ordinary shares under the Dividend Reinvestment element of the Plan
Mr S M Bicknell	Acquisition of 32 Ordinary shares under the Dividend Reinvestment element of the Plan
Mr E J Gray	Acquisition of 32 Ordinary shares under the Dividend Reinvestment element of the Plan
Mr S A Hussain	Acquisition of 2 Ordinary shares under the Dividend Reinvestment element of the Plan
Mr D Learmouth	Acquisition of 32 Ordinary shares under the Dividend Reinvestment element of the Plan
Dr D Pulman	Acquisition of 14 Ordinary shares under the Dividend Reinvestment element of the Plan
Mr D S Redfern	Acquisition of 32 Ordinary shares under the Dividend Reinvestment element of the Plan
Ms C Thomas	Acquisition of 32 Ordinary shares under the Dividend Reinvestment element of the Plan

The Company and the above-mentioned persons were advised of this information on 14 April 2009.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Deputy Company Secretary
14 April 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 14, 2009

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc